The “MIPI-genetic” (“MIPI-g”) which was developed for younger MCL patients and adds KMT2D mutations and TP53 disruptions to MIPI-c identifies a high-risk group with a 4-year PFS and OS probability of 11.5% and 44.9% [12]. The gene discussed is TP53; the disease is mantle cell lymphoma.